What is the current valuation of the Pemphigus Market as of 2025?

The Pemphigus Market valuation was 578.9 USD Million in 2024. Read More

What is the projected market size for the Pemphigus Market by 2035?

The market is projected to reach 1410.37 USD Million by 2035. Read More

What is the expected CAGR for the Pemphigus Market during the forecast period 2025 - 2035?

The expected CAGR for the Pemphigus Market during this period is 8.39%. Read More

Which companies are the key players in the Pemphigus Market?

Key players include Roche, Bristol-Myers Squibb, Novartis, Amgen, Sanofi, Merck & Co., Pfizer, GSK, and Eli Lilly. Read More

How does the Pemphigus Vulgaris segment perform in terms of market valuation?

The Pemphigus Vulgaris segment had a valuation of 300.0 USD Million in 2024 and is projected to reach 700.0 USD Million. Read More

What are the market valuations for different treatment types in the Pemphigus Market?

Corticosteroids were valued at 200.0 USD Million, while biologics reached 150.0 USD Million in 2024. Read More

What is the market size for the Pediatric demographic in the Pemphigus Market?

The Pediatric demographic was valued at 100.0 USD Million in 2024, with projections indicating growth. Read More

What is the valuation of the Immunology application segment in the Pemphigus Market?

The Immunology application segment had a valuation of 144.0 USD Million in 2024, with future growth anticipated. Read More

How does the market for intravenous treatments compare to other routes of administration?

Intravenous treatments were valued at 231.78 USD Million in 2024, indicating a strong preference among treatment routes. Read More

What is the projected growth for the Geriatric demographic in the Pemphigus Market?

The Geriatric demographic was valued at 132.9 USD Million in 2024, with expectations for substantial growth by 2035. Read More

Pemphigus Market

ID: MRFR/Pharma/5024-HCR

100 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Pemphigus Market Research Report Information  By Type (Pemphigus Vulgaris and Others), by Diagnosis (Skin Peeling, Endoscopy, and Others), by Treatment (Corticosteroid, Biological Therapies, and Others), by End-Users (Hospitals and Others)– Forecast Till 2035

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Application (USD Million) | |
  1. 4.1.1 Dermatology | |
  2. 4.1.2 Oncology | |
  3. 4.1.3 Immunology | |
  4. 4.1.4 Transplantation |
2. 4.2 Healthcare, BY Type of Pemphigus (USD Million) | |
  1. 4.2.1 Pemphigus Vulgaris | |
  2. 4.2.2 Pemphigus Foliaceus | |
  3. 4.2.3 Paraneoplastic Pemphigus |
3. 4.3 Healthcare, BY Treatment Type (USD Million) | |
  1. 4.3.1 Corticosteroids | |
  2. 4.3.2 Immunosuppressants | |
  3. 4.3.3 Biologics | |
  4. 4.3.4 Plasmapheresis |
4. 4.4 Healthcare, BY Route of Administration (USD Million) | |
  1. 4.4.1 Oral | |
  2. 4.4.2 Intravenous | |
  3. 4.4.3 Subcutaneous |
5. 4.5 Healthcare, BY Patient Demographics (USD Million) | |
  1. 4.5.1 Adults | |
  2. 4.5.2 Pediatric | |
  3. 4.5.3 Geriatric |
6. 4.6 Healthcare, BY Region (USD Million) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Roche (CH) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bristol-Myers Squibb (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Novartis (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Amgen (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Sanofi (FR) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Merck & Co. (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Pfizer (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 GSK (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Eli Lilly (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY APPLICATION |
7. 6.4 US MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
8. 6.5 US MARKET ANALYSIS BY TREATMENT TYPE |
9. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
10. 6.7 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
11. 6.8 CANADA MARKET ANALYSIS BY APPLICATION |
12. 6.9 CANADA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
13. 6.10 CANADA MARKET ANALYSIS BY TREATMENT TYPE |
14. 6.11 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
15. 6.12 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION |
18. 6.15 GERMANY MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
19. 6.16 GERMANY MARKET ANALYSIS BY TREATMENT TYPE |
20. 6.17 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
21. 6.18 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
22. 6.19 UK MARKET ANALYSIS BY APPLICATION |
23. 6.20 UK MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
24. 6.21 UK MARKET ANALYSIS BY TREATMENT TYPE |
25. 6.22 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
26. 6.23 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
27. 6.24 FRANCE MARKET ANALYSIS BY APPLICATION |
28. 6.25 FRANCE MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
29. 6.26 FRANCE MARKET ANALYSIS BY TREATMENT TYPE |
30. 6.27 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
31. 6.28 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
32. 6.29 RUSSIA MARKET ANALYSIS BY APPLICATION |
33. 6.30 RUSSIA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
34. 6.31 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE |
35. 6.32 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
36. 6.33 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
37. 6.34 ITALY MARKET ANALYSIS BY APPLICATION |
38. 6.35 ITALY MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
39. 6.36 ITALY MARKET ANALYSIS BY TREATMENT TYPE |
40. 6.37 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
41. 6.38 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
42. 6.39 SPAIN MARKET ANALYSIS BY APPLICATION |
43. 6.40 SPAIN MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
44. 6.41 SPAIN MARKET ANALYSIS BY TREATMENT TYPE |
45. 6.42 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
46. 6.43 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY APPLICATION |
54. 6.51 CHINA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
55. 6.52 CHINA MARKET ANALYSIS BY TREATMENT TYPE |
56. 6.53 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
57. 6.54 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
58. 6.55 INDIA MARKET ANALYSIS BY APPLICATION |
59. 6.56 INDIA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
60. 6.57 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
61. 6.58 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
62. 6.59 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
63. 6.60 JAPAN MARKET ANALYSIS BY APPLICATION |
64. 6.61 JAPAN MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
65. 6.62 JAPAN MARKET ANALYSIS BY TREATMENT TYPE |
66. 6.63 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
67. 6.64 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
73. 6.70 MALAYSIA MARKET ANALYSIS BY APPLICATION |
74. 6.71 MALAYSIA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
75. 6.72 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE |
76. 6.73 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
77. 6.74 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
78. 6.75 THAILAND MARKET ANALYSIS BY APPLICATION |
79. 6.76 THAILAND MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
80. 6.77 THAILAND MARKET ANALYSIS BY TREATMENT TYPE |
81. 6.78 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
82. 6.79 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
83. 6.80 INDONESIA MARKET ANALYSIS BY APPLICATION |
84. 6.81 INDONESIA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
85. 6.82 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE |
86. 6.83 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
87. 6.84 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
88. 6.85 REST OF APAC MARKET ANALYSIS BY APPLICATION |
89. 6.86 REST OF APAC MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
90. 6.87 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE |
91. 6.88 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
92. 6.89 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY APPLICATION |
95. 6.92 BRAZIL MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
96. 6.93 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE |
97. 6.94 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
98. 6.95 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
99. 6.96 MEXICO MARKET ANALYSIS BY APPLICATION |
100. 6.97 MEXICO MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
101. 6.98 MEXICO MARKET ANALYSIS BY TREATMENT TYPE |
102. 6.99 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
103. 6.100 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
104. 6.101 ARGENTINA MARKET ANALYSIS BY APPLICATION |
105. 6.102 ARGENTINA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
106. 6.103 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE |
107. 6.104 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
108. 6.105 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
125. 6.122 REST OF MEA MARKET ANALYSIS BY APPLICATION |
126. 6.123 REST OF MEA MARKET ANALYSIS BY TYPE OF PEMPHIGUS |
127. 6.124 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE |
128. 6.125 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
129. 6.126 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million) |
138. 6.135 HEALTHCARE, BY TYPE OF PEMPHIGUS, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY TYPE OF PEMPHIGUS, 2024 TO 2035 (USD Million) |
140. 6.137 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million) |
142. 6.139 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million) |
144. 6.141 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.2.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.2.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.3.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.3.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.3.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.4.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.4.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.4.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.5.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.5.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.5.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.6.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.6.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.6.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.7.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.7.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.7.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.8.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.8.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.8.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.9.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.9.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.9.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.10.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.10.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.10.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.11.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.11.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.11.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.12.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.12.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.12.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.13.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.13.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.13.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.14.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.14.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.14.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.15.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.15.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.15.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.16.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.16.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.16.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.17.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.17.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.17.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.18.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.18.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.18.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.19.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.19.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.19.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.20.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.20.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.20.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.21.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.21.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.21.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.22.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.22.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.22.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.23.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.23.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.23.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.24.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.24.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.24.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.25.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.25.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.25.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.26.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.26.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.26.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.27.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.27.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.27.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.28.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.28.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.28.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.29.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.29.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.29.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.30.2 BY TYPE OF PEMPHIGUS, 2025-2035 (USD Million) | |
  3. 7.30.3 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  5. 7.30.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Application (USD Million, 2025-2035)

Dermatology
Oncology
Immunology
Transplantation

Healthcare By Type of Pemphigus (USD Million, 2025-2035)

Pemphigus Vulgaris
Pemphigus Foliaceus
Paraneoplastic Pemphigus

Healthcare By Treatment Type (USD Million, 2025-2035)

Corticosteroids
Immunosuppressants
Biologics
Plasmapheresis

Healthcare By Route of Administration (USD Million, 2025-2035)

Oral
Intravenous
Subcutaneous

Healthcare By Patient Demographics (USD Million, 2025-2035)

Adults
Pediatric
Geriatric

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓

Pemphigus Market

Pemphigus Market Research Report Information&nbsp; By Type (Pemphigus Vulgaris and Others), by Diagnosis (Skin Peeling, Endoscopy, and Others), by Treatment (Corticosteroid, Biological Therapies, and Others), by End-Users (Hospitals and Others)&ndash; Forecast Till 2035